leadf
logo-loader
viewEmyria Ltd
(
ASX:EMD
)

Emyria to accelerate FDA and TGA CBD registration programs with Altasciences deal

Emyria Ltd (ASX:EMD)'s Michael Winlo tells Proactive's Andrew Scott they've contracted a leading North American drug manufacturer to deliver a range of novel, synthetic cannabinoid-based (CBD) medicines for its Australian and US drug registration program. They've engaged Altasciences, an award-winning contract drug manufacturer with more than 1,000 employees and seven locations across the US and Canada, to deliver a range of proprietary, synthetic cannabinoid-based capsules utilising a unique drug delivery approach.

Quick facts: Emyria Ltd

Follow
ASX:EMD

Price: 0.235 AUD

Market Cap: $59.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Emyria talks potential for new MDMA-analogues in treatment of Parkinson’s...

Emyria Ltd (ASX:EMD)'s Michael Winlo discusses with Proactive promising results from a previously published study assessing the effects of MDMA (ecstasy) and a unique MDMA-analogue (UWA-101) in a Parkinson’s disease (PD) model. He says the results indicate that both MDMA and UWA-101 extend the...

2 weeks, 3 days ago

2 min read